Although we are still living in a world largely dominated by COVID-19, here at Baker, we feel it’s important to still continue to support those working in patient and clinical care across the globe.
As vaccines are rolled out in many countries, the hope for a new normality could soon be on the horizon. At Baker, we have been #SupportingScience since 1951 and with new vaccines, therapeutics and discoveries now worldwide, we will continue to do so now more than ever!
As part of our #SupportingScience campaign, Dr. Ox is launching a new interview series in January 2021.
Make sure you subscribe, as Baker’s Director of Scientific Applications, Krista Rantanen Ph.D. poses some unexpected questions to the leading scientists of our time!
We would like to wish you a Happy Holidays and a wonderful New Year.
We look forward to seeing you in 2021!
AstraZeneca and The University of Oxford released results from its Phase 3 analysis of its COVID-19 vaccine candidate, AZD1222.
Drawn from two separate regimens, a half dose giving 90% efficacy and two full doses giving 62% efficacy, the pooled efficacy rate totalled 70%. Discover more.
New research has shed light on the role of antibodies and immune cells in the protection against SARS-CoV-2.
The findings have important implications for the development of SARS-CoV-2 vaccines and immune based therapeutics.
Almac Sciences received a $500,000 grant from the COVID-19 Therapeutics Accelerator to develop manufacturing processes for the antiviral drug, Remdesivir.
The drug is the first to receive approval of the FDA as a treatment for COVID-19.
From aligning ourselves with industry leading experts, Baker has a strong understanding of the wider industry and the complex problems that our customers face.
Visit our collaboration page on the website for more information.
Following on from last month’s Fact or Fiction focus on Neurodegenerative diseases, researchers at Case Western Reserve University School of Medicine identified a molecular pathway in Alzheimer’s disease.
The new discovery could lead to developments in therapeutics for the disease.
Did you see the review Dr. Ox shared on the role of hypoxia inducible factor-1 in cancer stem cells?
Head over to Twitter and see the latest content from Baker’s Director of Scientific Applications.
A recent study has shown that Aprotinin, a drug that is well known for reducing the risk of bleeding during surgery can stop the novel Coronavirus from entering and infecting host cells.
Johnson & Johnson has launched a second global phase 3 trial for its Janssen COVID-19 vaccine candidate.
This time, they are looking to explore a 2-dose regimen.
Find out more!
Sign up to our monthly newsletter to stay up to date on everything that’s going on at Baker.